Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection

• Published in: Cell Vol. 184; no. 7; pp. 1804 - 1820.e16
• Main Authors: Winkler, Emma S., Gilchuk, Pavlo, Yu, Jinsheng, Bailey, Adam L., Chen, Rita E., Chong, Zhenlu, Zost, Seth J., Jang, Hyesun, Huang, Ying, Allen, James D., Case, James Brett, Sutton, Rachel E., Carnahan, Robert H., Darling, Tamarand L., Boon, Adrianus C.M., Mack, Matthias, Head, Richard D., Ross, Ted M., Crowe, James E., Diamond, Michael S.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.04.2021
• Subjects: Animals; Antibodies, Monoclonal - immunology; Antibodies, Monoclonal - therapeutic use; Antibodies, Neutralizing - immunology; Antibodies, Neutralizing - therapeutic use; Antibodies, Viral - immunology; Antibodies, Viral - therapeutic use; antibody; CD8+ T cells; CD8-Positive T-Lymphocytes - cytology; CD8-Positive T-Lymphocytes - immunology; Chlorocebus aethiops; CHO Cells; COVID-19 - immunology; COVID-19 - therapy; COVID-19 infection; Cricetulus; Disease Models, Animal; disease prevention; effector function; Female; Humans; Immunoglobulin Fc Fragments - immunology; inflammation; loss-of-function mutation; lung; lungs; Male; mechanics; mechanism of action; Mice; Mice, Inbred C57BL; monocytes; mouse model; pathogenesis; respiratory tract diseases; RNA sequencing; SARS-CoV-2; SARS-CoV-2 - immunology; Severe acute respiratory syndrome coronavirus 2; therapeutics; therapy; tissue repair; transcription (genetics); Vero Cells; Viral Load; RNA sequencing; lung; effector function; monocytes; pathogenesis; SARS-CoV-2; CD8+ T cells; antibody; mouse model; therapy

SARS-CoV-2 has caused the global COVID-19 pandemic. Although passively delivered neutralizing antibodies against SARS-CoV-2 show promise in clinical trials, their mechanism of action in vivo is incompletely understood. Here, we define correlates of protection of neutralizing human monoclonal antibod...